Innate Pharma S.A. ADS (IPHA)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Innate Pharma is an experimental immunotherapy company with 120 employees. Its pipeline includes Lacutamab in Phase II, IPH4502, and Monalizumab. But pipelines are not earnings. The figures I have show a business that is burning money: FairStock's ROCE is -46.60%, its Altman Z-score is -17.72, and its Piotroski F-score is 0/9. FairStock's P/E of -2.49 at the $1.47 close on 2026-10-13 tells me there are no positive earnings to value. P/B is unavailable, no dividend is paid, and the FairStock score is 20/100. Market cap is $136.1M. The competitive moat, if any, rests on intellectual property and clinical data, not on durable cost advantages or pricing power. In biotech, science can be a lottery ticket; Graham wants demonstrated earning power and a margin of safety. Growth trajectory is binary: clinical trial readouts can create value or destroy it. The 52-week range of $1.17 to $2.71 shows volatility. The Lynch category is none because only 0 years of filed results are available—insufficient history. This is not a business I can underwrite with conventional value tools. The price may be near the low end of its range, but cheapness without profits or assets is not a margin of safety. I would need to see cash runway, trial success, and eventual revenue. Until then, it is speculation, not investment.

In plain English: Innate Pharma is a small French company with 120 employees that develops immune-based cancer treatments. The business looks weak on the numbers given: it is losing money, has very weak financial strength scores, and pays no dividend. At $1.47 on 2026-10-13, the price is near the low end of its 52-week range, but without profits or a proven earnings record it does not look like a classic cheap bargain; it looks like a speculative experimental medicine story.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer